Bayer And Consumer Health, Like Hand In Glove
“This is an amazing time to be in consumer health. Why would you get rid of an amazing business?” says Heiko Schipper, Bayer's consumer health chief since 2018.
You may also be interested in...
Fred Hassan, a director with private equity firm Warburg Pincus and an OTC industry veteran, recalls when consumer health meant nonprescription drugs and when self-care was a concept, not a description for consumers’ health care choices.
Sanofi will look to offload around 150 OTC brands as part of a radical overhaul of its Consumer Healthcare operation. The new head of the business Julie Van Ongevalle has unveiled a wide-ranging turnaround plan with the goal of transforming Sanofi into the OTC market leader.
Big pharmas' agreement could put consumer health where Pfizer wants, entirely in its rear-view mirror, and points GSK toward what it wants, more research and development funding freed up for the pharmaceutical ingredient operations that are its chief revenue drivers. All-equity deal, giving GSK 68% control and expected to close in 2019 second half, also likely will boost investors' confidence in the firms as both have been dogged by pressure to sell, spin-off or otherwise divest their consumer businesses.